Oxford-based Psychedelic medicine company Beckley Psytech has appointed a number of individuals to their Scientific Advisory Board, and it’s just as star-studded as imagined.
For those familiar with psychedelic research, the names need no introduction:
- Professor Guy Goodwin, Senior Research Fellow at the Department of Psychiatry, The University of Oxford
- Dr Robin L. Carhart-Harris PhD, Director of the Centre for Psychedelic Research at Imperial College London
- Professor Matthew W. Johnson PhD, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine
- Frederick Reinholdt MA, Senior Therapist in Psychedelics at The Institute of Psychiatry, Psychology and Neuroscience, King’s College London
These appointments represent decades of leading research and expertise, which will now help to drive forward Beckley’s own research programme, in conjunction with the Beckley Foundation. The board will oversee the Company’s psychedelic drug development pipeline, which seeks to bring psychedelic substances into the realm of licensed pharmaceuticals.
This pipeline includes their exploration of a synthetic pharmaceutical formulation of 5-MeO-DMT, a short-acting psychedelic agent.
Beckley Psytech hopes that these psychedelic drugs will treat psychiatric and neurological disorders, and this vision was validated by a successful £3m funding round earlier this year.
Commenting on these appointments, Lady Amanda Feilding – cofounder and Chair of the Scientific Advisory Board – said:
The expansion of the Scientific Advisory Board adds further depth and resource to Beckley Psytech’s strong foundations in psychedelic medicinal research, and more momentum to our mission of bringing safe and effective pharmaceutical-standard psychedelic medicines to patients in need.Amanda Feilding, cofounder and Chair of the Scientific Advisory Board, Beckley Psytech
Feilding went on to explain:
These appointments come at a pivotal time as we advance our lead programme on 5-MeO-DMT as well as expanding our research of other psychedelic agents, which we hope will offer transformative treatments for patients suffering from a variety of debilitating illnesses. We’re excited by the world-class knowledge, experience and strategic counsel the new Scientific Advisers bring to the Beckley team.Amanda Feilding, cofounder and Chair of the Scientific Advisory Board, Beckley Psytech
You can learn more about the appointments via Beckley Psytech’s website, here.
Related Interview: Beckley Psytech’s CEO
We spoke to Cosmo Feilding Mellen, CEO of the Company, last month. Read the full interview here.